ArticleVascular health and risk management2025
Burden, Trends, Risk Factors, and Forecast of Ischemic Heart Disease, Rheumatic Heart Disease, and Atrial Fibrillation and Flutter From 1990 to 2040: A Comparative Analysis of China, the United States, and Europe Based on the Global Burden of Disease Study and the Potential Impact of the COVID-19 Pandemic.
Article in Vascular health and risk management, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Atrial fibrillation and atrial flutter in China: trends and projections to 2050 from GBD 2023.Internal and emergency medicine · 2026Article
- A Global Study of Skin and Subcutaneous Diseases Among Individuals Under 20 Years of Age.Clinical, cosmetic and investigational dermatology · 2026Article
- Ischemic Heart Disease and the Epidemiologic Transition: Progress without Reduction in Global Burden.Discoveries (Craiova, Romania)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Understanding the global burden of cardiovascular diseases is essential for developing effective preventive strategies and guiding policy measures worldwide. Despite significant advances in diagnosis and treatment, cardiovascular diseases remain the leading cause of morbidity and mortality across all regions. Assessing their temporal trends and regional disparities can provide valuable insights for optimizing resource allocation and improving global health outcomes. Methods: We used data from the Global Burden of Disease 2021 (GBD 2021) to analyze the incidence, prevalence, deaths, Years Lived with Disability (YLDs), Years of Life Lost (YLLs), and Disability-Adjusted Life Years (DALYs) of three major cardiovascular diseases-Atrial Fibrillation and Flutter (AFF), Ischemic Heart Disease (IHD), and Rheumatic Heart Disease (RHD)-globally and in the People's Republic of China, Europe, and the United States of America (USA). Comparative analyses and projections were performed through 2040. Results: Globally, age-standardized incidence rates (ASIRs, per 100,000 population) from 1990 to 2021 slightly declined for AFF (52.51 to 52.12) and IHD (419.54 to 372.9) but increased for RHD (44.87 to 50.74). In China and the USA, AFF incidence rose (42.63 to 44.92 and 75.22 to 89.18, respectively), and IHD incidence in China increased (315.31 to 365.67). RHD incidence declined across all three regions. Notably, AFF and IHD trends increased after 2019, potentially related to COVID-19. Conclusion: This study reveals distinct global and regional trends in the burden of AFF, IHD, and RHD from 1990 to 2021. The burden of AFF and IHD declined in most regions but showed a potential increase during the COVID-19 pandemic, while RHD continued to rise, particularly in low-SDI (Sociodemographic Index) countries. These findings provide valuable evidence to guide targeted prevention strategies and optimize resource allocation in global cardiovascular health policy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.